tbuckley/cabot-search huggingface dataset:
Implementing Quality Improvement for Psychosocial Interventions
Authors: Sean Grant, Evan Mayo-Wilson, Paul Montgomery
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
US to require safety warnings for Essure sterilization device
Authors: Michael McCarthy
Journal: BMJ (2016)

New warnings must be printed on the labels of the implantable sterilization device Essure after reports of serious side effects, the US Food and Drug Administration (FDA) has announced.

The administration has also ordered the device manufacturer, Bayer, to conduct a postmarket surveillance study to compare adverse events with Essure with those seen with tubal ligation.

“The actions we are taking today will encourage conversations between women and their doctors to help patients make more informed decisions about whether Essure is right for them,” said William Maisel, deputy director for science …
Airway dysbiosis: <i>Haemophilus influenzae</i> and <i>Tropheryma</i> in poorly controlled asthma
Authors: Jodie L. Simpson, Joshua Daly, Katherine J. Baines, Ian A. Yang, John W. Upham, Paul N. Reynolds, Sandra Hodge, Alan L. James, Philip Hugenholtz, Dana Willner, Peter G. Gibson
Journal: European Respiratory Journal (2015)

Asthma is a chronic inflammatory disorder of the airways where bacteria may act as protagonists of chronic inflammation. Little is known about the relation of airway inflammation to the presence of specific bacterial taxa. We sought to describe the sputum microbiome in adults with poorly controlled asthma. DNA was extracted from induced sputum and microbial communities were profiled using 16S rRNA pyrosequencing. Bacterial species were characterised, and the relationship between microbial populations, asthma inflammatory subtypes and other covariates was explored. Real-time PCR was used to identify Tropheryma whipplei and Haemophilus influenzae in sputum. Adults with neutrophilic asthma had reduced bacterial diversity and species richness. Tropheryma was identified and confirmed with real-time PCR in 12 (40%) participants. Haemophilus occurred most often in a group of younger atopic males with an increased proportion of neutrophils. PCR confirmed the presence of H. influenzae in 35 (76%) participants with poorly controlled asthma. There are phenotype-specific alterations to the airway microbiome in asthma. Reduced bacterial diversity combined with a high prevalence of H. influenzae was observed in neutrophilic asthma, whereas eosinophilic asthma had abundant T. whipplei .
Minority with HIV infection must be identified
Authors: E. L Smith, A. Raddadi, O. B. Obaid, S. Abdullah
Journal: BMJ (1995)

EDITOR,--We fully support the conclusions of J A Evans and colleagues.1 In Saudi Arabia, where we practise, all antenatal patients are tested for HIV. Current philosophy emphasises respect for the human rights of people infected with HIV. The associated policies give little consideration to the rights of those who are not infected—and who is more innocent than the unborn child? Present policies concerning anonymity, confidentiality, and the rights of …
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
Authors: Carl Koschmann, Anda-Alexandra Calinescu, Felipe J. Nunez, Alan Mackay, Janet Fazal-Salom, Daniel Thomas, Flor Mendez, Neha Kamran, Marta Dzaman, Lakshman Mulpuri, Johnathon Krasinkiewicz, Robert Doherty, Rosemary Lemons, Jacqueline A. Brosnan-Cashman, Youping Li, Soyeon Roh, Lili Zhao, Henry Appelman, David Ferguson, Vera Gorbunova, Alan Meeker, Chris Jones, Pedro R. Lowenstein, Maria G. Castro
Journal: Science Translational Medicine (2016)

The loss of ATRX impairs DNA repair, promoting glioma growth but enhancing sensitivity to DNA-damaging therapies.
Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years
Authors: Shameem Mahmood, Sajitha Sachchithanantham, Frank Bridoux, Thirusha Lane, Lisa Rannigan, Darren Foard, Rabya Sayed, Ketna Patel, Marianna Fontanna, Carol Whelan, Helen J Lachmann, Julian D Gillmore, Philip N Hawkins, Ashutosh Wechalekar
Journal: Blood (2013)
Persistence of Immunoglobulin and Complement Components C4 and C3 Bound to Guinea Pig Tumor Cells
Authors: Martin Segerling, Sarkis H. Ohanian, Tibor Borsos
Journal: JNCI Journal of the National Cancer Institute (1976)

Guinea pig hepatoma cells (line-10) growing as ascites were studied for the presence of immunoglobulin, C4, and C3 (components of complement) on their surfaces. Immunoglobulin, C4, and C3 content increased with length of time spent in the peritoneal cavity. The persistence of these factors bound in vivo or in vitro was also determined. Complement-fixing (CF) activity of cellbound antibody disappeared from the surface more rapidly at 37 degrees C than at 4 degrees C; the continued presence of cellbound immunoglobulin in non-complement-fixing form could be demonostrated at either temperature. No CF activity was released into the medium. C4 and C3 were released into the medium and could be demonstrated in the medium by immunochemical methods.
The psychiatric chief resident: does gender make a difference?
Authors: M D Kessler, C Hellekson-Emery, J F Wilder
Journal: American Journal of Psychiatry (1982)

The authors surveyed women and men psychiatric chief residents who were near the end of their residency training. The findings documented the active participation of women in leadership roles as psychiatric residents in education, administration, and clinical care. Men and women reported remarkably similar job descriptions, opportunities, and difficulties. Women were less likely than men to participate in research activities during the chief residency or to accept full-time faculty positions after training.
Panitumumab (PMAB) in combination with chemotherapy (CT) versus CT alone: health-related quality of life (HRQOL) in patients (PTS) with wild-type (WT) KRAS metastatic colorectal cancer (MCRC)
Authors: Marc Peeters, Lee Bennett, Zhongyun Zhao, Beth Barber, Xiaolei Zhou, Jessica Zhang, Feng Xu, Jeffery Wiezorek, Jean-Yves Douillard
Journal: Annals of Oncology (2011)
Comparative anti-oxidant effects of carbocysteine and fluticasone propionate in cigarette smoke stimulated airway epithelial cells
Authors: Elisabetta Pace, Maria Ferraro, Serena Di Vincenzo, Rossella Balsamo, Luigi Lanata, Andreina Bruno, Luana Lipari, Mark Gjomarkaj
Journal: European Respiratory Journal (2012)

Cigarette smoke extracts (CSE) induce oxidative stress, an important feature in chronic obstructive pulmonary disease (COPD). Oxidative stress contributes to the poor clinical efficacy of corticosteroids. Carbocysteine, an anti-oxidant and mucolytic agent, is effective in reducing the severity and the rate of exacerbations in COPD patients. The effects of carbocysteine on CSE induced oxidative stress in nasal and in bronchial epithelial cells as well as the comparison of these anti-oxidant effects of carbocysteine with those of fluticasone propionate are largely unknown.

The present study was aimed to assess:

the effects of carbocysteine (10-4 M) in cell survival and intracellular reactive oxygen species (ROS) production in CSE stimulated bronchial (16-HBE) and in CSE stimulated nasal (RPMI 2650) epithelial cells and to compare these effects with those of fluticasone propionate (10-8 M).

Carbocysteine or fluticasone propionate did not induce cell necrosis (propidium positive cells) or cell apoptosis (Annexin V positive/propidium negative cells) in 16 HBE and in RPMI 2650 at the tested concentrations. CSE increased intracellular ROS production in 16HBE and in RPMI 2650. Fluticasone propionate was not able to significantly reduce intracellular ROS production in both 16HBE and in RPMI 2650. Carbocysteine was able to significantly reduce intracellular ROS production and was more effective than fluticasone propionate in reducing these CSE mediated effects in both cell lines.

In conclusion, the present study provides compelling evidences that carbocysteine may be considered a promising strategy in diseases associated to corticosteroid resistance.
<i>Helicobacter pylori</i>and gut microbiota modulate energy homeostasis prior to inducing histopathological changes in mice
Authors: Yalda Khosravi, Ralph M Bunte, Kher Hsin Chiow, Tuan Lin Tan, Whye Yen Wong, Qian Hui Poh, Ignatius Mario Doli Sentosa, Shih Wee Seow, Arlaine Anne Amoyo, Sven Pettersson, Mun Fai Loke, Jamuna Vadivelu
Journal: Gut Microbes (2016)

Helicobacter pylori have been shown to influence physiological regulation of metabolic hormones involved in food intake, energy expenditure and body mass. It has been proposed that inducing H. pylori-induced gastric atrophy damages hormone-producing endocrine cells localized in gastric mucosal layers and therefore alter their concentrations. In a recent study, we provided additional proof in mice under controlled conditions that H. pylori and gut microbiota indeed affects circulating metabolic gut hormones and energy homeostasis. In this addendum, we presented data from follow-up investigations that demonstrated H. pylori and gut microbiota-associated modulation of metabolic gut hormones was independent and precedes H. pylori-induced histopathological changes in the gut of H. pylori-infected mice. Thus, H. pylori-associated argumentation of energy homeostasis is not caused by injury to endocrine cells in gastric mucosa.
Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance
Authors: Wantong Song, Zhaohui Tang, Na Shen, Haiyang Yu, Yanjie Jia, Dawei Zhang, Jian Jiang, Chaoliang He, Huayu Tian, Xuesi Chen
Journal: Journal of Controlled Release (2016)
Can an excess of estimated over-predicted creatinine generation be a discriminating test for noncompliance in continuous ambulatory peritoneal dialysis?
Authors: A H Tzamaloukas
Journal: Journal of the American Society of Nephrology (1995)

Journal of the American Society of Nephrology : JASN 6(5):p 1519-1520, November 1995. | DOI: 10.1681/ASN.V651519
Abstract 14580: Predictors for Permanent Pacemaker Implantation After Corevalve Implantation in Patients Without Preexisting ECG Conduction Disturbances. The Role of a New Echocardiographic Index
Authors: Andreas Synetos, Konstantinos Toutouzas, Konstantinos Stathogiannis, George Latsios, Stella Brili, Antonios Mastrokostopoulos, Georgios Benetos, Archontoula Michelongona, Alex Pw Lee, Adrian Cheong, Cheuk-Man Yu, Christodoulos Stefanadis
Journal: Circulation (2013)

Purpose: The aim of this study was to assess the anatomical and electrocardiograhical (ECG) predictors of postoperative permanent pacemaker (PPM) implantation, in patients without ECG conduction di...
Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes
Authors: James J. Chamberlain, Andrew S. Rhinehart, Charles F. Shaefer, Annie Neuman
Journal: Annals of Internal Medicine (2016)

The American Diabetes Association (ADA) published the 2016 Standards of Medical Care in Diabetes (Standards) to provide clinicians, patients, researchers, payers, and other interested parties with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.The ADA Professional Practice Committee performed a systematic search on MEDLINE to revise or clarify recommendations based on new evidence. The committee assigns the recommendations a rating of A, B, or C, depending on the quality of evidence. The E rating for expert opinion is assigned to recommendations based on expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community was incorporated into the 2016 revision.The synopsis focuses on 8 key areas that are important to primary care providers. The recommendations highlight individualized care to manage the disease, prevent or delay complications, and improve outcomes.
Abstract 2763: Predictive Value of Ankle-Brachial-Index and Plaques in the Carotid and Femoral Arteries on Cardiovascular Events and Mortality in a Population-Based Study with 13-Years of Follow-Up
Authors: Claudia Lamina, Christa Meisinger, Iris M Heid, Hannelore Loewel, Barbara Rantner, Wolfgang Koenig, Florian Kronenberg
Journal: Circulation (2006)

Background: Peripheral arterial occlusive disease (PAOD) is associated with a high risk of cardiovascular morbidity and mortality. However, long-term prospective population-based studies on the val...
EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
Authors: Yong Jia, Jose Juarez, Jie Li, Mari Manuia, Matthew J. Niederst, Celin Tompkins, Noelito Timple, Mei-Ting Vaillancourt, AnneMarie Culazzo Pferdekamper, Elizabeth L. Lockerman, Chun Li, Jennifer Anderson, Carlotta Costa, Debbie Liao, Eric Murphy, Michael DiDonato, Badry Bursulaya, Gerald Lelais, Jordi Barretina, Matthew McNeill, Robert Epple, Thomas H. Marsilje, Nuzhat Pathan, Jeffrey A. Engelman, Pierre-Yves Michellys, Peter McNamara, Jennifer Harris, Steven Bender, Shailaja Kasibhatla
Journal: Cancer Research (2016)

Abstract Non–small cell lung cancer patients carrying oncogenic EGFR mutations initially respond to EGFR-targeted therapy, but later elicit minimal response due to dose-limiting toxicities and acquired resistance. EGF816 is a novel, irreversible mutant-selective EGFR inhibitor that specifically targets EGFR-activating mutations arising de novo and upon resistance acquisition, while sparing wild-type (WT) EGFR. EGF816 potently inhibited the most common EGFR mutations L858R, Ex19del, and T790M in vitro, which translated into strong tumor regressions in vivo in several patient-derived xenograft models. Notably, EGF816 also demonstrated antitumor activity in an exon 20 insertion mutant model. At levels above efficacious doses, EGF816 treatment led to minimal inhibition of WT EGFR and was well tolerated. In single-dose studies, EGF816 provided sustained inhibition of EGFR phosphorylation, consistent with its ability for irreversible binding. Furthermore, combined treatment with EGF816 and INC280, a cMET inhibitor, resulted in durable antitumor efficacy in a xenograft model that initially developed resistance to first-generation EGFR inhibitors via cMET activation. Thus, we report the first preclinical characterization of EGF816 and provide the groundwork for its current evaluation in phase I/II clinical trials in patients harboring EGFR mutations, including T790M. Cancer Res; 76(6); 1591–602. ©2016 AACR.
Concanavalin A-Activated Suppressor Cell Activity in Peripheral Blood Lymphocytes of Urologic Cancer Patients&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: W J Catalona, T L Ratliff, R E McCool
Journal: JNCI Journal of the National Cancer Institute (1980)

Concanavalin A (Con A)-inducible suppressor cell activity in peripheral blood lymphocytes (PBL) of urologic cancer patients and of appropriate controls with benign urologic disorders was measured concurrently. Although the proliferative responses to Con A of the cancer patients were significantly lower than those of controls, no difference in Con A-induced suppressor cell activity was demonstrated between cancer patients and controls when tested under a variety of conditions. Moreover, regression analysis revealed no correlation between the proliferative response to Con A and suppressor cell activity in either cancer patients or controls. The results indicated that Con A-inducible suppressor cell activity was unaltered in urologic cancer patients and suggested that suppressor cells of the type that can be activated by Con A were not involved in the general immunologic impairment frequently associated with urologic cancer.
Activation, Activities and Pharmacologically Active Products of Complement
Authors: Walther Vogt
Journal: Pharmacological Reviews (1974)

Background  Developing countries grapple with inadequate funding amidst high burden of diseases. Africa is home to 9 of the 22 countries with a high tuberculosis (TB) burden and to 29 of the 41 countries with a high TB-HIV burden. Kenya is among the high TB and high TB-HIV burden countries. The Western Kenya region has the highest burden of TB and HIV. North-South partnerships are pivotal in ameliorating funding gaps in clinical research.  Methods  While optimising existing infrastructure and organising programme support (i.e sensitisation and awareness creation, leading to study participant recruitment), from 2005 to date we conducted with multiple North-South collaborators capacity strengthening, TB prevalence survey, observational studies, operational research, and vaccine and drug trials.  Results  TB prevalence survey showed 600 cases per 100,000 population, TB epidemiological studies among adolescents and infants yielded 680 and 900/100,000 population respectively while 2 TB vaccine trials among infants and adults were conducted in Siaya. Three TB drug trials and a TB patient observational cum bio-bank study were concluded in Kisumu. KEMRI TB laboratory was upgraded from BSL2 to BSL3, was ISO-accredited in 2013, renewed in 2015 and 2017 and supports TB programme health facilities with retreatment specimens, supervision and mentorship. Over 25 operational TB studies grouped into community and case detection (increasing case detection), diagnostic and molecular (new diagnostic methods) and epidemiology studies (testing and monitoring cohorts for epidemiological questions) were implemented. Five PhDs, 9 Master’s, 2 Postgraduate Diplomas, 6 Bachelor’s degrees and 10 Diplomas have been supported. Siaya clinical research center was built while in Kisumu an adolescent clinic was constructed. This work involved 18 northern and 26 southern partners. Over 35 publications have been published out of these collaborations.  Conclusion  North-South collaborations provided funding, expertise and resources to harness research capacity of KEMRI; hence the need to foster a global networking culture.
Abstract A38: Remodeling of the malignant bone marrow niche represents a therapeutic target.
Authors: Timothy B. Campbell, Emmanuelle Passegué
Journal: Clinical Cancer Research (2015)

Abstract Myeloproliferative neoplasms (MPNs) are malignant diseases of the hematopoietic stem cell (HSC). Targeting driver mutations in these diseases has had variable success. In chronic myelogenous leukemia (CML), targeting the BCR/ABL pathway has completely changed the way these patients are treated; however, there still remain a significant proportion of patients who have no targetable mutation for therapy and treatments centered on non-cell autonomous pathways of disease progression may have significant value. Previously, our lab showed that malignant myeloid cells from a mouse model of CML overexpressing BCR/ABL (BA mice) expand a remodeled mesenchymal stem cell (MSC) derived osteoblast population which leads to a fibrotic bone marrow (BM) niche and preserves malignant hematopoiesis (Schepers et al. Cell Stem Cell 2013; 13: 285-299). Disrupting the establishment of this fibrotic niche hopefully could delay clinical MPN progression and restore normal hematopoiesis. Bisphosphonates are known to act locally in the BM microenvironment on many cell types and improve the survival of patients with BM-involved disease, including multiple myeloma and breast cancer (Modi and Lentzsch. Leukemia 2012; 26:589-594). The focus of our current studies is to test the effect of zoledronic acid (ZA), a widely used bisphosphonate, on in vitro MSC fibrotic colony formation induced by malignant CML cells. Using whole BM from BA or control mice co-cultured with wild type MSCs, we found that ZA potently inhibited the increase in MSC colony formation induced by CML cells. The significant four-fold increase in MSC colony size (measured by cell number per colony) in BA co-cultures was completely negated by ZA at concentrations as low as 500 nM. The BA co-cultures were exquisitely sensitive to ZA and no breakthrough colonies were seen as compared to a 65 percent reduction in colony size in control co-cultures with 500 nM ZA. Our results suggest that zoledronic acid could be an interesting therapeutic compound to target the fibrotic BM niche in MPNs. Ongoing studies seek to understand the mechanism of action of ZA and to test its efficacy in preventing fibrosis and restoring a healthy BM niche in the BA model of CML. The goal is also to expand these results to other, more strongly fibrotic, mouse models of MPNs and human MPN samples. Citation Format: Timothy B. Campbell, Emmanuelle Passegué. Remodeling of the malignant bone marrow niche represents a therapeutic target. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A38.